- 移动端
乔默生物技术（上海）有限公司品牌商
5 年
手机商铺
商家活跃：
产品热度：
- NaN
- 0.2999999999999998
- 0.2999999999999998
- 2.3
- 2.3
推荐产品
新冠蛋白SARS-CoV-2 Nucleocapsid Protein (Omicron B1.1.529 Variant), Tag Free, HEK293
品牌：Chamot Biotech/乔默生物
￥5400
咨询
技术资料&文献引用/正文
凋亡试剂盒/Apoptosis Detection kit
221 人阅读发布时间：2022-08-31 09:51
1. Pterostilbene prevents AKT-ERK axis-mediated polymerization of surface fibronectin on suspended lung cancer cells independently of apoptosis and suppresses metastasis.Journal of Hematology & Oncology volume 10, Article number: 72 (2017).(IF 11.059)
2. p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells.Pharmacological Research. 119 (2017) 443–462.(IF 5.893)
3. Effect of Metformin Nanoparticle-Mediated Thioredoxin Interacting Protein Expression on Oxaliplatin-Induced Peripheral Neuralgia. J Nanosci Nanotechnol. 2020 Oct 1;20(10):6123-6132.(IF 1.354)
2. p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells.Pharmacological Research. 119 (2017) 443–462.(IF 5.893)
3. Effect of Metformin Nanoparticle-Mediated Thioredoxin Interacting Protein Expression on Oxaliplatin-Induced Peripheral Neuralgia. J Nanosci Nanotechnol. 2020 Oct 1;20(10):6123-6132.(IF 1.354)
4. Platelets are highly efficient and efficacious carriers for tumor-targeted nano-drug delivery. Drug Delivery. 2022, VOL. 29, NO. 1, 937–949. (IF 6.419)
5. Chlorin e6-Induced Photodynamic Effect Polarizes the Macrophage Into an M1 Phenotype Through Oxidative DNA Damage and Activation of STING. Frontiers in Pharmacology. 2022 Mar 3;13:837784. (IF 5.810)
6. A nanoreactor boosts chemodynamic therapy and ferroptosis for synergistic cancer therapy using molecular amplifer dihydroartemisinin. J Nanobiotechnology. 2022 May 14;20(1):230. (IF 9.464)
7. Dihydroartemisinin remodels macrophage into an M1 phenotype via ferroptosis-mediated DNA damage.Front Pharmacol. 2022 Aug 11;13:949835. (IF 5.81)
6. A nanoreactor boosts chemodynamic therapy and ferroptosis for synergistic cancer therapy using molecular amplifer dihydroartemisinin. J Nanobiotechnology. 2022 May 14;20(1):230. (IF 9.464)
7. Dihydroartemisinin remodels macrophage into an M1 phenotype via ferroptosis-mediated DNA damage.Front Pharmacol. 2022 Aug 11;13:949835. (IF 5.81)